PerkinElmer’s life science and diagnostics spinoff rebranded as Revvity earlier this week.

The company, which serves customers across the pharmaceutical, biotech, diagnostic labs sectors, said in a media release that the name comes from the word “revolution” as well as “vita” which means “life” in Latin. PerkinElmer spun out the medtech business line in March.

As it relates to the existing brand architecture, Revvity said its BioLegend, Euroimmun, Tulip Diagnostics and ViaCord franchises will retain their respective names as unique product lines.

Meanwhile, Revvity’s scientific software platform, previously known as PerkinElmer Informatics, will be rebranded as Revvity Signals Software, Inc. Additionally, PerkinElmer Genomics will be replaced by Revvity Omics, while several brands like Horizon Discovery, Nexcelom Bioscience and Omni International will identify as Revvity and maintain their specific product names.

Going forward, the company will trade under the stock ticker symbol “RVTY” starting on Tuesday, May 16.

Last year, Revvity generated more than $3 billion in revenue and has more than 11,000 employees.

“The unveiling of Revvity is the capstone of a nearly year-long journey that has transformed who we are and reinforces why our work matters,” Revvity CEO Prahlad Singh said in a statement. “At Revvity, we are united with our customers to impact health across the lifespan. Our purpose is to expand the boundaries of human potential through science. We view the challenges facing our customers as a call to action.”

Revvity marks yet another healthcare company rebranding itself.

Late last month, Norwegian biotech Targovax announced plans to rebrand as Circio to mark the shift from being a clinical stage immuno-oncology company to one focused on circular RNA (circRNA) therapeutics.

A couple months prior, KemPharm unveiled its new name: Zebra Therapeutics. The decision to rebrand came as the company focuses its efforts on the rare diseases space. 

Around the same time, Cancer Treatment Centers of America was renamed by City of Hope following a $390 million acquisition in 2022. All of the organization’s facilities will transition to the new parent name.

On the agency side, Austin healthcare agency HCB Health rebranded itself as Boundless Life Sciences Group.